Cinclus Pharma Holding AB (publ) (STO:CINPHA)

Market Cap	587.31M -18.4%
Revenue (ttm)	35.18M -9.0%
Net Income	-269.38M
EPS	-5.25
Shares Out	46.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,196
Open	12.38
Previous Close	12.20
Day's Range	12.22 - 12.80
52-Week Range	10.48 - 19.64
Beta	-0.05
Analysts	Strong Buy
Price Target	45.25 (+264.33%)
Earnings Date	Aug 19, 2026

About Cinclus Pharma Holding AB

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquar...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 17
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CINPHA

Financial Performance

In 2025, Cinclus Pharma Holding AB's revenue was 57.47 million, an increase of 1154.80% compared to the previous year's 4.58 million. Losses were -183.97 million, 9.49% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for CINPHA stock is "Strong Buy." The 12-month stock price target is kr 45.25, which is an increase of 264.33% from the latest price.

Price Target

kr 45.25

(264.33% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 4, 2026

Data Sources Report a data error